<DOC>
	<DOCNO>NCT01064401</DOCNO>
	<brief_summary>The primary study objective test superiority Daclizumab High Yield Process ( DAC HYP ) compare interferon β 1a ( IFN β-1a ) prevent multiple sclerosis ( MS ) relapse participant relapse remit multiple sclerosis . The secondary study objective test superiority DAC HYP compare IFN β-1a slow functional decline disability progression maintain quality life participant population .</brief_summary>
	<brief_title>Efficacy Safety BIIB019 ( Daclizumab High Yield Process ) Versus Interferon β 1a Participants With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Must confirm diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) , cranial magnetic resonance imaging ( MRI ) demonstrate lesion ( ) consistent MS Must baseline Expanded Disability Status Scale ( EDSS ) 0.0 5.0 , inclusive Male subject female subject childbearing potential must willing practice effective contraception study willing able continue contraception 4 month last dose study treatment Key Known intolerance , contraindication , history noncompliance Avonex® 30 µg History treatment Daclizumab High Yield Process ( Dac HYP ) History malignancy History severe allergic anaphylactic reaction Known hypersensitivity study drug excipients History abnormal laboratory result indicative significant disease History human immunodeficiency virus ( HIV ) immunodeficient condition History drug alcohol abuse ( define Investigator ) within 2 year prior randomization History seizure disorder unexplained blackout OR history seizure within 6 month prior Baseline History suicidal ideation episode clinically severe depression ( determined Investigator ) within 3 month prior Day 1 An MS relapse occur within 50 day prior randomization AND/OR subject stabilize previous relapse prior randomization Known history , positive screen test result hepatitis C virus hepatitis B virus Varicella herpes zoster virus infection severe viral infection within 6 week screen Exposure varicella zoster virus within 21 day screen NOTE : Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>